These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol. Kinon BJ, Kollack-Walker S, Stauffer V, Liu-Seifert H. J Clin Psychopharmacol; 2012 Jun; 32(3):420-2. PubMed ID: 22561475 [No Abstract] [Full Text] [Related]
8. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Suzuki Y, Someya T, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S. Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317 [Abstract] [Full Text] [Related]
14. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Volavka J, Nolan KA, Kline L, Czobor P, Citrome L, Sheitman B, Lindenmayer JP, McEvoy J, Lieberman JA. Schizophr Res; 2005 Jul 01; 76(1):127-9. PubMed ID: 15927808 [No Abstract] [Full Text] [Related]
15. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Reschke RW. Dis Nerv Syst; 1974 Mar 01; 35(3):112-5. PubMed ID: 17894080 [Abstract] [Full Text] [Related]
17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Clin Ther; 2008 Dec 01; 30(12):2378-86. PubMed ID: 19167596 [Abstract] [Full Text] [Related]